Compare NTST & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | ZLAB |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 2017 |
| Metric | NTST | ZLAB |
|---|---|---|
| Price | $19.66 | $17.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $22.02 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.1M | 795.4K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | 38.46 |
| EPS | ★ 0.06 | N/A |
| Revenue | $195,006,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $19.03 | $9.75 |
| Revenue Next Year | $16.25 | $26.03 |
| P/E Ratio | $332.67 | ★ N/A |
| Revenue Growth | ★ 19.79 | 15.33 |
| 52 Week Low | $16.04 | $15.96 |
| 52 Week High | $21.30 | $44.34 |
| Indicator | NTST | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 33.77 |
| Support Level | $17.67 | $15.96 |
| Resistance Level | $21.13 | $19.64 |
| Average True Range (ATR) | 0.33 | 0.68 |
| MACD | -0.11 | -0.20 |
| Stochastic Oscillator | 0.00 | 15.71 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.